UNSPSC 51152027: Idrocilamide

This classification denotes a muscle relaxant with the molecular formula C11H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6C816LUB1O, chemically known as 2-propenamide, n-(2-hydroxyethyl)-3-phenyl- but generally known as idrocilamide, which bears US NIH Compound Identifier 1550874. European Medicines Agency schedules Idrocilamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08121MIG. The term IDROCILAMIDE is an International Non-Proprietary Name.

UNSPSC 51152027 Idrocilamide, a Commodity code, nominally designates a specific pharmaceutical compound, but recent state and local procurement activity tagged to this code does not reflect procurement of idrocilamide itself. Instead, Seminole County, Florida has posted an IFB (Solicitation Number IFB60459723LAS) for naloxone and safe drug deactivation systems—opioid-antagonist medications and related equipment for community health use—with annual volumes of 1,900 units of naloxone and 800 deactivation systems, quarterly delivery to the county's community health facility, and a two-year initial term with optional one-year renewal. The Texas Health and Human Services Commission has simultaneously issued an RFI (HHS0017013) exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels, seeking vendor capabilities in direct contracting, outcomes-based pricing, and volume fulfillment for state employee and health plan beneficiaries. The code appears to reflect a taxonomic mislabeling rather than actual idrocilamide procurement; the opportunities suggest state and local buyers are using the commodity slot to tag pharmaceutical acquisition and pharmacy program modernization work more broadly.

Issuing bodies are limited in the recent record to a single Florida county government and a state health agency. Geographic activity centers on Florida and Texas. Seminole County's naloxone procurement is an IFB with response due July 26, 2023 (posted June 30, 2026), requiring electronic bid submission through the county's e-Procurement Portal, unit pricing by line item, drug-free workplace and E-Verify compliance, and workers' compensation and general liability insurance. The Texas HHS RFI, posted April 3, 2026, with response due the same day, is a preliminary market-intelligence vehicle with no formal competitive timeline, set-asides, or award value specified; it precedes a likely future formal RFP. Neither opportunity identifies set-aside designations or restricted disadvantaged-enterprise programs. Given the narrow and unrelated nature of recent activity under this code, the commodity shows minimal relevant procurement volume for the stated pharmaceutical class.